Biomarkers for the acute respiratory distress syndrome: How to make the diagnosis more precise

Annals of Translational Medicine

Volumn 5, Issue 14, 2017, Pages

  Isabel Garcia Laorden M ^a,b   Lorente, José A ^a,c,d   Flores, Carlos ^a,e   Slutsky, Arthur S ^f,g   Villar, Jesús ^a,b,f  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^c HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^d UNIVERSIDAD EUROPEA DE MADRID   (Spain)

^e HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acute respiratory distress syndrome (ARDS); Biomarkers; Diffuse alveolar damage (DAD); Endothelial lung injury; Epithelial lung injury

Indexed keywords

3 METHYLHEPTANE; ACETALDEHYDE; ADVANCED GLYCATION END PRODUCT; ANGIOPOIETIN 2; BIOLOGICAL MARKER; FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 8; OCTANE; PROCOLLAGEN; PROCOLLAGEN PEPTIDE; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; BRONCHOALVEOLAR LAVAGE FLUID; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; ENDOTHELIUM INJURY; EXPIRED AIR; LUNG INJURY; OUTCOME ASSESSMENT; PATIENT MONITORING; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 85026360580     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.21037/atm.2017.06.49     Document Type: Review

References (76)

1. Ashbaugh DG, Bigelow DB, Petty TL, et al. Acute respiratory distress in adults. Lancet 1967;2:319-23
2. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818-24
3. Ranieri VM, Rubenfeld GD, Thompson BT et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307:2526-33
4. Villar J. What is the acute respiratory distress syndrome? Respir Care 2011;56:1539-45
5. Villar J, Pérez-Méndez L, Blanco J, et al. A universal definition of ARDS: the PaO2/FiO2 ratio under a standard ventilatory setting-a prospective, multicenter, validation study. Intensive Care Med 2013;39:583-92
6. Villar J, Blanco J, Kacmarek RM. Current incidence and outcome of the acute respiratory distress syndrome. Curr Opin Crit Care 2016;22:1-6
7. Tomashefski JF Jr. Pulmonary pathology of acute respiratory distress syndrome. Clin Chest Med 2000;21:435-66
8. Guérin C, Thompson T, Brower R. The ten diseases that look like ARDS. Intensive Care Med 2015;41:1099-102
9. Villar J, Slutsky AS. GOLDEN anniversary of the acute respiratory distress syndrome: still much work to do! Curr Opin Crit Care 2017;23:4-9
10. de Hemptinne Q, Remmelink M, Brimioulle S, et al. ARDS: a clinicopathological confrontation. Chest 2009;135:944-9
11. Schuster DP. The search for "objective" criteria of ARDS. Intensive Care Med 2007;33:400-2
12. Villar J, Blanco J, Kacmarek RM. Acute respiratory distress syndrome definition: do we need a change? Curr Opin Crit Care 2011;17:13-17
13. Sweeney RM, McAuley D. Acute respiratory distress syndrome. Lancet 2016;388:2416-30
14. Jameson JL, Longo DL. Precision medicine-personalized, problematic and promising. N Engl J Med 2015;372:2229-34
15. Rubin R. A precision medicine approach to clinical trials. JAMA 2016;316:1953-5
16. Terpstra ML, Aman J, van Nieuw Amerongen GP, et al. Plasma biomarkers for acute respiratory distress síndrome: a systematic review and meta-analysis. Crit Care Med 2014;42:691-700
17. Blondonnet R, Constantin JM, Sapin V, et al. A Pathophysiologic Approach to Biomarkers in Acute Respiratory Distress Syndrome. Dis Markers 2016;2016:3501373
18. Bos LD, Weda H, Wang Y, et al. Exhaled breath metabolomics as a non-invasive diagnostic tool for acute respiratory distress syndrome. Eur Respir J 2014;44:188-197
19. Villar J, Pérez-Méndez L, Espinosa E, et al. Serum lipopolysaccharide binding protein levels predict severity of lung injury and mortality in patients with severe sepsis. PLoS One 2009;4:e6818
20. McShane LM, Cavenagh MM, Lively TG, et al. Criteria for the use of omics-based predictors in clinical trials. Nature 2013;502:317-20
21. Meyer NJ, Christie JD. Genetic heterogeneity and risk of acute respiratory distress syndrome. Semin Respir Crit Care Med 2013;34:459-74
22. Acosta-Herrera M, Pino-Yanes M, Pérez-Méndez L, et al. Assessing the quality of studies supporting genetic susceptibility and outcomes of ARDS. Front Genet 2014;5:20
23. Horhat FG, Gundogdu F, David LV, et al. Early Evaluation and Monitoring of Critical Patients with Acute Respiratory Distress Syndrome (ARDS) Using Specific Genetic Polymorphisms. Biochem Genet 2017;55:204-11
24. Howrylak JA, Dolinay T, Lucht L, et al. Discovery of the gene signature for acute lung injury in patients with sepsis. Physiol Genomics 2009;37:133-9
25. Wang Z, Beach D, Su L, et al. A genome-wide expression analysis in blood identifies pre-elafin as a biomarker in ARDS. Am J Respir Cell Mol Biol 2008;38:724-32
26. Stringer KA, Serkova NJ, Karnovsky A, et al. Metabolic consequences of sepsis-induced acute lung injury revealed by plasma 1H-nuclear magnetic resonance quantitative metabolomics and computational analysis. Am J Physiol Lung Cell Mol Physiol 2011;300:L4-L11
27. Shirasawa M, Fujiwara N, Hirabayashi S, et al. Receptor for advanced glycation end-products is a marker of type I lung alveolar cells. Genes Cells 2004;9:165-74
28. Calfee CS, Ware LB, Eisner MD, et al. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 2008;63:1083-9
29. Mauri T, Masson S, Pradella A, et al. Elevated plasma and alveolar levels of soluble receptor for advanced glycation end-products are associated with severity of lung dysfunction in ARDS patients. Tohoku J Exp Med 2010;222:105-12
30. Nakamura T, Sato E, Fujiwara N, et al. Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome. Clin Biochem 2011;44:601-4
31. Jabaudon M, Futier E, Roszyk L, et al. Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients. Crit Care Med 2011;39:480-8
32. Fremont RD, Koyama T, Calfee CS, et al. Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis. J Trauma 2010;68:1121-7
33. Ware LB, Koyama T, Zhao Z, et al. Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome. Crit Care 2013;17:R253
34. Scholz A, Plate KH, Reiss Y. Angiopoietin-2: a multifaceted cytokine that functions in both angiogenesis and inflammation. Ann N Y Acad Sci 2015;1347:45-51
35. Bhandari V, Choo-Wing R, Lee CG, et al. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med 2006;12:1286-93
36. van der Heijden M, van Nieuw Amerongen GP, Koolwijk P, et al. Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients. Thorax 2008;63:903-9
37. Wada T, Jesmin S, Gando S, et al. The role of angiogenic factors and their soluble receptors in acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) associated with critical illness. J Inflamm (Lond) 2013;10:6
38. Agrawal A, Matthay MA, Kangelaris KN, et al. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am J Respir Crit Care Med 2013;187:736-42
39. Gallagher DC, Parikh SM, Balonov K, et al. Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. Shock 2008;29:656-61
40. Calfee CS, Gallagher D, Abbott J, et al. Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance. Crit Care Med 2012;40:1731-7
41. Calfee CS, Janz DR, Bernard GR, et al. Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies. Chest 2015;147:1539-48
42. Sorensen GL, Husby S, Holmskov U. Surfactant protein A and surfactant protein D variation in pulmonary disease. Immunobiology 2007;212:381-416
43. Endo S, Sato N, Nakae H, et al. Surfactant protein A and D (SP-A, AP-D) levels in patients with septic ARDS. Res Commun Mol Pathol Pharmacol 2002;111:245-51
44. Determann RM, Royakkers AA, Haitsma JJ, et al. Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients. BMC Pulm Med 2010;10:6
45. Eisner MD, Parsons P, Matthay MA, et al. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax 2003;58:983-8
46. Cheng IW, Ware LB, Greene KE, et al. Prognostic value of surfactant proteins A and D in patients with acute lung injury. Crit Care Med 2003;31:20-7
47. Ware LB, Koyama T, Billheimer DD, et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 2010;137:288-96
48. Calfee CS, Ware LB, Glidden DV, et al. Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury. Crit Care Med 2011;39:711-7
49. Han S, Mallampalli RK. The acute respiratory distress syndrome: from mechanism to translation. J Immunol 2015;194:855-60
50. Donnelly SC, Strieter RM, Kunkel SL, et al. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patients. Lancet 1993;341:643-7
51. McClintock D, Zhuo H, Wickersham N, et al. Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury. Crit Care 2008;12:R41
52. Parsons PE, Eisner MD, Thompson BT, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med 2005;33:1-6
53. Cartin-Ceba R, Hubmayr RD, Qin R, et al. Predictive value of plasma biomarkers for mortality and organ failure development in patients with acute respiratory distress syndrome. J Crit Care 2015;30:219.e1-7
54. Fein A, Grossman RF, Jones JG, et al. The value of edema fluid protein measurement in patients with pulmonary edema. Am J Med 1979;67:32-8
55. Janz DR, Ware LB. Biomarkers of ALI/ARDS: pathogenesis, discovery, and relevance to clinical trials. Semin Respir Crit Care Med 2013;34:537-48
56. Evans CR, Karnovsky A, Kovach MA, et al. Untargeted LC-MS metabolomics of bronchoalveolar lavage fluid differentiates acute respiratory distress syndrome from health. J Proteome Res 2014;13:640-9
57. Galani V, Tatsaki E, Bai M, et al. The role of apoptosis in the pathophysiology of acute respiratory distress síndrome (ARDS): an up-to-date cell specific review. Pathol Res Pract 2010;206:145-50
58. Albertine KH, Soulier MF, Wang Z, et al. Fas and fas ligand are up-regulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome. Am J Pathol 2002;161:1783-96
59. Hashimoto S, Kobayashi A, Kooguchi K, et al. Upregulation of two death pathways of perforin/granzyme and FasL/Fas in septic acute respiratory distress syndrome. Am J Respir Crit Care Med 2000;161:237-43
60. Chesnutt AN, Matthay MA, Tibayan FA, et al: Early detection of type III procollagen peptide in acute lung injury. Pathogenetic and prognostic significance. Am J Respir Crit Care Med 1997;156:840-5
61. Clark JG, Milberg JA, Steinberg KP, et al. Type III procollagen peptide in the adult respiratory distress syndrome. Association of increased peptide levels in bronchoalveolar lavage fluid with increased risk of death. Ann Intern Med 1995;122:17-23
62. Meduri GU, Tolley EA, Chinn A, et al. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med 1998;158:1432-41
63. Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006;354:1671-84
64. de Torre C, Ying SX, Munson PJ, et al. Proteomic analysis of inflammatory biomarkers in bronchoalveolar lavage. Proteomics 2006;6:3949-57
65. Chang DW, Hayashi S, Gharib SA, et al. Proteomic and computational analysis of bronchoalveolar proteins during the course of the acute respiratory distress syndrome. Am J Respir Crit Care Med 2008;178:701-9
66. Bhargava M, Becker TL, Viken KJ, et al. Proteomic profiles in acute respiratory distress syndrome differentiates survivors from non-survivors. PLoS One 2014;9:e109713
67. Vaschetto R, Corradi M, Goldoni M, et al. Sampling and analyzing alveolar exhaled breath condensate in mechanically ventilated patients: a feasibility study. J Breath Res 2015;9:047106
68. Gessner C, Dihazi H, Brettschneider S, et al. Presence of cytokeratins in exhaled breath condensate of mechanical ventilated patients. Respir Med 2008;102:299-306
69. Boots AW, Bos LD, van der Schee MP, et al. Exhaled molecular fingerprinting in diagnosis and monitoring: validating volatile promises. Trends Mol Med 2015;21:633-44
70. Bos LD, Wang Y, Weda H, et al. A simple breath sampling method in intubated and mechanically ventilated critically ill patients. Respir Physiol Neurobiol 2014;191:67-74
71. Bos LD, Schultz MJ, Sterk PJ. Exhaled breath profiling for diagnosing acute respiratory distress syndrome. BMC Pulm Med 2014;14:72
72. Bos LD, Sterk PJ, Schultz MJ. Measuring metabolomics in acute lung injury: choosing the correct compartment? Am J Respir Crit Care Med 2012;185:789
73. Proudfoot AG, Hind M, Griffiths MJ. Biomarkers of acute lung injury: worth their salt? BMC Med 2011;9:132
74. Lyman GH, Moses HL. Biomarker tests for molecularly targeted therapies-the key to unlocking precision medicine. N Engl J Med 2016;375:4-6
75. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007;6:287-93
76. Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2014;2:611-20